J.‐F. Yale

2.3k total citations · 1 hit paper
21 papers, 1.8k citations indexed

About

J.‐F. Yale is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Public Health, Environmental and Occupational Health. According to data from OpenAlex, J.‐F. Yale has authored 21 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Surgery and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in J.‐F. Yale's work include Diabetes Treatment and Management (10 papers), Diabetes Management and Research (8 papers) and Pancreatic function and diabetes (7 papers). J.‐F. Yale is often cited by papers focused on Diabetes Treatment and Management (10 papers), Diabetes Management and Research (8 papers) and Pancreatic function and diabetes (7 papers). J.‐F. Yale collaborates with scholars based in Canada, United States and United Kingdom. J.‐F. Yale's co-authors include Hertzel C. Gerstein, Gary Meininger, Dennis K. Yue, Elias David‐Neto, Keith Usiskin, Bertrand Cariou, Ewa Wajs, George L. Bakris, Liwen Xi and Lawrence A. Leiter and has published in prestigious journals such as Diabetes Care, Diabetes and Journal of the American Society of Nephrology.

In The Last Decade

J.‐F. Yale

21 papers receiving 1.7k citations

Hit Papers

Efficacy and safety of canagliflozin in subjects with typ... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
    2013 418 citations J.‐F. Yale, George L. Bakris et al. Diabetes Obesity and Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.‐F. Yale Canada 17 1.4k 530 389 217 163 21 1.8k
Sreenivasa Rao Kondapally Seshasai United Kingdom 12 1.0k 0.7× 588 1.1× 366 0.9× 173 0.8× 119 0.7× 21 2.2k
Jeffrey L. Probstfield United States 11 2.0k 1.4× 692 1.3× 781 2.0× 374 1.7× 44 0.3× 17 2.5k
N. J. Morrish United Kingdom 8 810 0.6× 242 0.5× 222 0.6× 73 0.3× 90 0.6× 10 1.4k
Anna Tavridou Greece 22 526 0.4× 371 0.7× 365 0.9× 121 0.6× 116 0.7× 70 2.0k
Michael S. Kostapanos Greece 25 801 0.6× 1.1k 2.0× 352 0.9× 123 0.6× 73 0.4× 79 2.5k
Antonios Douros Germany 24 556 0.4× 267 0.5× 252 0.6× 181 0.8× 86 0.5× 85 1.6k
Ulrik Haagen Panton Denmark 9 971 0.7× 312 0.6× 405 1.0× 94 0.4× 74 0.5× 17 1.8k
K L Woods United Kingdom 18 333 0.2× 228 0.4× 245 0.6× 138 0.6× 200 1.2× 54 2.0k
Annabel Acs Canada 7 916 0.7× 288 0.5× 391 1.0× 89 0.4× 69 0.4× 10 1.8k
Celine Foote Australia 13 941 0.7× 639 1.2× 321 0.8× 127 0.6× 29 0.2× 21 1.9k

Countries citing papers authored by J.‐F. Yale

Since Specialization
Citations

This map shows the geographic impact of J.‐F. Yale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.‐F. Yale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.‐F. Yale more than expected).

Fields of papers citing papers by J.‐F. Yale

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.‐F. Yale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.‐F. Yale. The network helps show where J.‐F. Yale may publish in the future.

Co-authorship network of co-authors of J.‐F. Yale

This figure shows the co-authorship network connecting the top 25 collaborators of J.‐F. Yale. A scholar is included among the top collaborators of J.‐F. Yale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.‐F. Yale. J.‐F. Yale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Reichert, Sonja M., Hanan Amadid, Uffe Christian Braae, et al.. (2023). CLINICAL OUTCOMES ASSOCIATED WITH THE USE OF ORAL SEMAGLUTIDE IN AN ADULT POPULATION WITH TYPE 2 DIABETES IN CANADA: A PROSPECTIVE REAL-WORLD STUDY (PIONEER REAL CANADA). Canadian Journal of Diabetes. 47(7). S96–S97. 1 indexed citations
2.
Yale, J.‐F., Vanita R. Aroda, B Charbonnel, et al.. (2018). Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes & Metabolism. 46(2). 110–118. 19 indexed citations
3.
Owens, David R., Timothy S. Bailey, Carmine G. Fanelli, J.‐F. Yale, & Geremia B. Bolli. (2018). Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation. Diabetes & Metabolism. 45(4). 330–340. 16 indexed citations
4.
Yale, J.‐F., G. Bakris, Bertrand Cariou, et al.. (2014). Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obesity and Metabolism. 16(10). 1016–1027. 224 indexed citations
5.
Yale, J.‐F., George L. Bakris, Bertrand Cariou, et al.. (2013). Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obesity and Metabolism. 15(5). 463–473. 418 indexed citations breakdown →
6.
Casanova, Amparo, Hwee Teoh, Hertzel C. Gerstein, et al.. (2012). Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. International Journal of Clinical Practice. 66(5). 457–464. 35 indexed citations
7.
8.
Khunti, Kamlesh, Salvatore Caputo, Taner Damcı, et al.. (2012). The safety and efficacy of adding once‐daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obesity and Metabolism. 14(12). 1129–1136. 44 indexed citations
9.
10.
Yale, J.‐F.. (2005). Oral Antihyperglycemic Agents and Renal Disease. Journal of the American Society of Nephrology. 16(3_suppl_1). S7–S10. 56 indexed citations
11.
Josse, Robert G., Eileen Ryan, Darren Lau, et al.. (2002). Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Research and Clinical Practice. 59(1). 37–42. 83 indexed citations
12.
Gougeon, Réjeanne, et al.. (2002). The prediction of resting energy expenditure in type 2 diabetes mellitus is improved by factoring for glycemia. International Journal of Obesity. 26(12). 1547–1552. 47 indexed citations
13.
Meneilly, Graydon S., E. A. Ryan, J. Radziuk, et al.. (2000). Effect of acarbose on insulin sensitivity in elderly patients with diabetes.. Diabetes Care. 23(8). 1162–1167. 108 indexed citations
14.
15.
Meltzer, S. J., Lawrence A. Leiter, Denis Daneman, et al.. (1998). 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Medical Association Journal. 159(8). 1–29. 307 indexed citations
16.
Yale, J.‐F., Mark Grose, Thomas A. Seemayer, & Errol B. Marliss. (1987). Immunological and Metabolic Concomitants of Cyclosporin Prevention of Diabetes in BB Rats. Diabetes. 36(6). 749–757. 14 indexed citations
17.
Yale, J.‐F., et al.. (1987). Urine C-peptide as index of integrated insulin secretion in hypocaloric states in obese human subjects. Diabetes. 36(4). 447–453. 3 indexed citations
18.
Yale, J.‐F., et al.. (1985). Time course of the lymphopenia in BB rats. Relation to the onset of diabetes. Diabetes. 34(10). 955–959. 12 indexed citations
19.
Yale, J.‐F., et al.. (1985). Effects of Cyclosporine on Glucose Tolerance in the Rat. Diabetes. 34(12). 1309–1313. 59 indexed citations
20.
Yale, J.‐F. & E. B. Marliss. (1984). Altered immunity and diabetes in the BB rat.. PubMed. 57(1). 1–11. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sreenivasa Rao Kondapally Seshasai Breakdown of academic impact, for papers by Jeffrey L. Probstfield Breakdown of academic impact, for papers by N. J. Morrish Breakdown of academic impact, for papers by Anna Tavridou Breakdown of academic impact, for papers by Michael S. Kostapanos Breakdown of academic impact, for papers by Antonios Douros Breakdown of academic impact, for papers by Ulrik Haagen Panton Breakdown of academic impact, for papers by K L Woods Breakdown of academic impact, for papers by Annabel Acs Breakdown of academic impact, for papers by Celine Foote
Rankless by CCL
2026